Analyst Ratings February 9, 2026

Bernstein Lifts HCA Healthcare Price Target to $541, Keeps Market Perform Rating

Analyst raises target on margin gains and buyback-driven shareholder yield, but valuation and medium-term EBITDA risks keep rating unchanged

By Sofia Navarro HCA
Bernstein Lifts HCA Healthcare Price Target to $541, Keeps Market Perform Rating
HCA

Bernstein SocGen Group has increased its 12-month price target on HCA Healthcare Inc to $541 from $503 while retaining a Market Perform rating. The firm cites margin efficiency and robust share repurchase activity as drivers for the higher target, and has modestly raised its EBITDA forecasts. At the same time, Bernstein points to valuation levels and potential moderating EBITDA growth as reasons for maintaining a neutral rating.

Key Points

  • Bernstein raised HCA’s price target to $541 from $503 but left the stock's rating at Market Perform.
  • The firm increased its EBITDA forecasts by 2-3% over the next five years, citing better expense ratios and modest improvements in rate and volume.
  • HCA reported Q4 2025 EPS of $8.01 versus an expected $7.45, while revenue slightly missed projections; management has been actively buying back shares, supporting a high shareholder yield.

Bernstein SocGen Group has raised its price target for HCA Healthcare Inc to $541.00 from $503.00 while maintaining a Market Perform rating on the shares. The investment firm highlighted HCA’s margin efficiency and significant share buyback capacity as key factors behind the move.

HCA shares are trading around $501.69, with a market capitalization of $114.48 billion. Bernstein updated its financial model after what it described as "a solid quarter of execution" from the healthcare provider. The firm noted that management has been aggressively repurchasing shares, a trend that has contributed to a high shareholder yield.

In its update, Bernstein raised its EBITDA forecasts for HCA by 2-3% over the next five years. The analyst house attributed the upward revisions to improved expense ratios and modestly stronger rate and volume dynamics. HCA’s reported EBITDA for the last twelve months stands at $15.49 billion, and its revenue growth rate is 7.08%.

Despite the higher price target and the upgraded EBITDA outlook, Bernstein elected to keep a Market Perform rating on HCA. The firm pointed to valuations that sit at the upper end of long-term ranges as a central concern. Bernstein also highlighted potential headwinds to future EBITDA expansion, citing a scenario in which rate growth moderates and compensation ratios stabilize after marked improvement over recent years.

Separately, HCA Healthcare reported fourth-quarter 2025 results that drew investor attention. The company posted earnings per share of $8.01, above analysts’ consensus of $7.45, representing a positive earnings surprise. Revenue for the quarter slightly missed projections, even as profitability outpaced expectations.

Those fourth-quarter outcomes — an EPS beat alongside a modest revenue shortfall — have informed market reactions and the analyst community’s assessment of HCA’s near-term financial performance. Bernstein’s adjustments reflect these developments, while its retained Market Perform rating underscores lingering valuation and growth uncertainties.


What this means for markets

  • Equity investors in the healthcare and hospital-services sectors will weigh the higher target against valuation concerns noted by Bernstein.
  • Fixed-income and credit-market participants may monitor HCA’s balance-sheet implications from continued buybacks and operating-margin trends.
  • Analysts and investors will track forthcoming quarters for confirmation of the margin and rate-volume improvements that underpin Bernstein’s forecast revisions.

Risks

  • Valuations are described as being at the high end of long-term ranges, which could limit upside for equity investors - impacting healthcare and broader equity markets.
  • Potential moderation in rate growth and stabilization of compensation ratios could weigh on future EBITDA expansion - relevant to hospital operators and healthcare services providers.
  • Continued aggressive share repurchases may influence balance-sheet flexibility and capital allocation, a consideration for credit markets and fixed-income investors.

More from Analyst Ratings

Stifel Lowers JFrog Target Citing AI-Driven Security Concerns; Maintains Buy Rating Feb 22, 2026 HSBC Lowers Synopsys Rating to Hold, Flags 2026 as Transition Year Feb 21, 2026 DA Davidson Cuts Uber Price Target Citing Elevated Investment; Buy Rating Intact Feb 20, 2026 Freedom Capital Markets Raises Freeport-McMoRan to Buy, Cites Copper Supply Tightness Feb 20, 2026 BofA Lifts CF Industries Price Target After Strong Q4 EBITDA; Maintains Underperform Rating Feb 20, 2026